Thymalin research guide
Historical thymic preparation name; current composition requires verification
An identity-first guide to Thymalin as a historical thymic preparation, explaining why a name and total mass do not define one peptide or prove equivalence.
AUS Peptide Supply editorial team01 · Identity
What the name identifies
Historical primary reports describe Thymalin or thymaline as a thymic preparation or polypeptide factor, including material obtained from calf thymus. Those descriptions do not establish whether a modern product is an extract, an isolated peptide or a defined mixture. Current composition must be documented independently.
02 · Evidence position
What the literature can support
The selected historical abstracts establish preparation terminology and report clinical or analytical observations, but they do not provide enough composition and trial-design detail to validate a modern catalogue material. Thymosin Alpha-1 is a separately defined peptide and should not be treated as a synonym.
03 · Study-level map
Evidence and its limits
How was the historical preparation described?
A 1984 report in 36 patients described thymaline obtained from calf thymus. This identifies the historical preparation context, not the source of current stock.
Limit: The indexed abstract does not provide a complete component profile or establish equivalence to a later product bearing the same name.
What kind of analytical work was reported?
A 1987 study developed an indirect enzyme immunoassay for thymalin, described as a polypeptide thymus factor.
Limit: An immunoassay response is not a complete sequence-level identification or quantitative profile of every component in a preparation.
Why distinguish Thymosin Alpha-1?
The original Thymosin Alpha-1 sequence study identified a particular 28-residue peptide. That level of molecular definition cannot be assigned to an unspecified preparation by name alone.
Limit: No claim is made that a Thymalin-labelled vial contains that peptide or any fixed proportion of it.
04 · Analytical context
Questions a batch record should answer
- 01Does the supplier identify the material as an extract, defined mixture or isolated compound?
- 02Are component identities, proportions and manufacturing origin documented for this exact material?
- 03Can the analytical method distinguish the intended preparation from similarly named thymic products?
05 · Boundary conditions
What this record does not establish
- The supplied composition is not established by the Thymalin name or a 10mg label.
- Historical calf-thymus origin must not be asserted for current stock without evidence.
- No verified APS CoA or component-resolved composition record is available for the associated product at publication.
Sources checked
- 1.Use of a thymus polypeptide preparation to diagnose and correct immune deficiency states in multiple sclerosis
Golovkin et al. — Zhurnal Nevropatologii i Psikhiatrii / PubMed · 1984 · Primary study
- 2.Immunoenzyme method of determining thymus polypeptide factor
Moskvicheva et al. — Zhurnal Mikrobiologii, Epidemiologii i Immunobiologii / PubMed · 1987 · Primary study
- 3.Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide
Goldstein et al. — Proceedings of the National Academy of Sciences / PubMed · 1977 · Primary study